Premium
Hepatitis C Virus Clearance in Older Adults
Author(s) -
Ippolito Antonio Massimo,
Iacobellis Angelo,
Milella Michele,
Conti Fabio,
Messina Vincenzo,
Valvano Maria Rosa,
Niro Grazia Anna,
Morisco Filomena,
Barone Michele,
Termite Antonio Patrizio,
Brancaccio Giuseppina,
Andriulli Angelo
Publication year - 2018
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/jgs.15140
Subject(s) - medicine , cirrhosis , hepatitis c virus , hepatocellular carcinoma , liver disease , gastroenterology , adverse effect , hepatitis c , fibrosis , immunology , virus
Objectives To determine whether older adults with the hepatitis C virus ( HCV ) achieve a sustained viral response ( SVR ) after treatment with direct‐acting antiviral therapy. Participants Individuals aged 80 and older with chronic HCV infection (N = 253; n = 213 with cirrhosis, n = 40 with advanced fibrosis). Measurements We investigated the efficacy, safety, and global clinical effect of treatment with different combinations of direct antiviral agents ( DAA s). Participants with cirrhosis were staged according to Child‐Pugh‐Turcotte class, Model for End‐Stage Liver Disease score, and the D'Amico staging system. The type and number of comorbidities at baseline and hepatic and nonhepatic events during follow‐up were registered. Results Ninety‐five percent of participants with cirrhosis and 95% of those with advanced fibrosis attained SVR . The rate was independent of sex, HCV genotype, and treatment schedule. During a mean follow‐up of 14 ± 4 months (range 5–23 months), 34 events occurred in 27 participants: 10 hepatocellular carcinomas, 12 hepatic decompensations, 9 nonhepatic events, 3 deaths. Multivariate analysis of risk factors for experiencing adverse events during follow up showed that participants in D'Amico Stages 4 and 5, with a baseline serum albumin level of 3.5 mg/ dL or less, and 3 or more comorbidities were the most at risk. Conclusion In a real‐world setting, DAA s are safe and effective in older adults with HCV ‐related advanced fibrosis or cirrhosis. Individuals with preserved albumin synthesis and fewer than 3 comorbidities at baseline have the most to gain from long‐term DAA therapy.